Evidence map›Paper›PMID 33948855›Full record

ArticleMolecular biology reports2021

Differentially expressed miR-20, miR-21, miR-100, miR-125a and miR-146a as a potential biomarker for prostate cancer.

Mohan Damodaran, Mohanapriya Chinambedu Dandapani, SimonDuraiRaj, SandhyaSundaram, S VenkatRamanan, Ilangovan Ramachandran, Vettriselvi Venkatesan

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Article
  3. MicroRNA dysregulation in male infertility: Insights into mechanisms, biomarkers, and therapeutic strategies- review.Mammalian genome : official journal of the International Mammalian Genome Society · 2025
    Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Mohan DamodaranDepartment of Human Genetics, Sri Ramachandra Institute of Higher Education and Research, Chennai, 600116, India.
Mohanapriya Chinambedu DandapaniCentral Research Facility, Sri Ramachandra Institute of Higher Education and Research, Chennai, India.
SimonDuraiRajDepartment of Pathology, Sri Ramachandra Institute of Higher Education and Research, Chennai, India.
SandhyaSundaramDepartment of Pathology, Sri Ramachandra Institute of Higher Education and Research, Chennai, India.
S VenkatRamananDepartment of Urology, Sri Ramachandra Institute of Higher Education and Research, Chennai, India.
Ilangovan RamachandranDepartment of Endocrinology, Dr. ALM PG Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai, 600113, India.
Vettriselvi VenkatesanDepartment of Human Genetics, Sri Ramachandra Institute of Higher Education and Research, Chennai, 600116, India. vettriselviv@sriramachandra.edu.in.ORCID http://orcid.org/0000-0003-2827-8680
Sri Ramachandra Institute of Higher Education and Research · INUniversity of Madras · IN

Funding

Department of Biotechnology, Government of India 6242-P58/RGCB/PMD/DBT/VVSL/2015
6 · The paper itself

Abstract

Prostate cancer is the leading cause of death among men worldwide. Deregulation of microRNAs has been reported in many cancers. Expression of microRNAs miR-20a-5p, miR-21-5p, miR-100-5p, miR-125a-5p and miR-146a-5p in tissue blocks of histologically confirmed prostate cancer patients compared with BPH patients, to identify potential microRNA biomarker for prostate cancer. MicroRNA was isolated and expression was quantified by qRT-PCR using Taqman Advanced microRNA assay kits. The interactions between the microRNA:target mRNA were predicted by using bioinformatics tools such as miRwalk and miRTargetlink. The experimentally validated targets were analysed using gprofiler to identify their molecular function, biological process and related pathways. The expression analysis revealed that miR-21 and miR-100 were significantly down-regulated whereas miR-125a was up-regulated in prostate cancer patients. Comparative analysis of the expression levels with tumor grading reveal that miR-100 was significantly down-regulated (p < 0.05) in high grade tumor, indicating that miR-100 associated with prostate cancer. ROC analysis revealed that combined analysis of down-regulated miRNAs (miR-21 and miR-100) shown AUC of 0.72 (95% CI 0.65-0.79). The combined analysis of all five miRNAs showed AUC of 0.87 (95% CI 0.81-0.92). The targets prediction analysis revealed several validated targets including BCL2, ROCK1, EGFR, PTEN, MTOR, NAIF1 and VEGFA. Our results provide evidence that combined analysis of all the five miRNAs as a panel can significantly improve the prediction level of the presence of prostate cancer and may be used as a potential diagnostic biomarker.

Indexed as

Gene Expression Regulation, NeoplasticAgedAged, 80 and overBiomarkers, TumorComputational BiologyHumansMaleMicroRNAsMiddle AgedProstatic NeoplasmsROC CurveBiomarkers, TumorMicroRNAsMIRN100 microRNA, humanMIRN125 microRNA, humanMIRN146 microRNA, humanMIRN21 microRNA, humanBenign Prostate Hyperplasia (BPH)BiomarkerFFPE (Formalin-Fixed Paraffin embedded)MicrornaProstate cancerROC (Receiver Operating Curve)Target enrichment

Identifiers

PMID33948855
OpenAlexW3157809633

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.